July 2, 2008
Multi-Year Clinical Study Data Suggest Use of FDA-Cleared Mobile Air Decontamination Unit, PlasmairT2006 With HEPA-MD(TM), Contributes to Reducing Incidence of Airborne Aspergillosis Infection
AirInSpace, a leading supplier of mobile devices that 'catch and inactivate' harmful and resistant biological particles from the air, announced today that data from a multi-year clinical study shows a significant reduction in aspergillosis infection rates in a standard hospital setting when using the Company's patented PlasmairT2006 mobile unit with HEPA-MD(TM) technology.
The data were presented by Ludwig Aho-Glele, M.D., Director of Infection Control and Hospital Epidemiologist at Dijon University Hospital, a 1600-bed academic teaching hospital in Dijon, France, during an educational symposium at the recent 2008 annual conference of the Association for Professionals in Infection Control & Epidemiology (APIC). The AirInSpace-sponsored symposium, "Strategies for Airborne Infection Control Under Challenging Environments and Patient Conditions", also included presentations from Michael S. Phillips, M.D., Hospital Epidemiologist, Infection Prevention and Control, New York University (NYU) Medical Center; and, Wayne R. Thomann, Ph.D., Director, Occupational and Environmental Safety Office, Duke University Health System.
"Invasive aspergillosis is a potentially deadly infection for immune-suppressed hospital patients: the Centers for Disease Control and Prevention (CDC) reports a mortality rate of 95 percent in immune-suppressed patients who are recipients of allogeneic bone marrow transplants and patients who have aplastic anemia," said Dr. Aho-Glele. "These patients need a highly protective environment. Our multi-year study demonstrates that the AirInSpace mobile system not only can protect these patients but also is a less costly solution for our hospital."
Aspergillus is a genus of some 200, highly airborne molds, some of which can be deadly, especially to immunocompromised hospital patients. Incidence rates of invasive aspergillosis have been reported as high as 26% in allogenic bone marrow transplant patients and 25% in acute leukemia patients. And in these immunocompromised patients who are infected by airborne aspergillosis spores, the scientific literature reports that death occurs in as many as nine out of 10 of these patients. The cost of extended hospitalization from invasive aspergillosis is estimated to be as high as $49,336 per case.
"In a hospital setting, construction work that liberates large amounts of Aspergillus spores is the major source of nosocomial aspergillosis," added Dr. Aho-Glele. "Given that we have commenced a major, long-term construction project right next door to high-risk clinical units such as our adult and pediatric hematology wards, we need to be extra diligent in preventing liberation of these spores that are the source of potentially lethal nosocomial aspergillosis."
AirInSpace's flagship product is an FDA-cleared mobile air-decontamination unit called PlasmairT2006 by AirInSpace. Its performance has been clinically proven to lower airborne biological loads and is now being used to combat nosocomial infection in high- risk areas of more than 100 hospitals and clinics, including hematology/oncology units and ICUs. Developed initially for use in Russia's MIR space station, the AirInSpace technology is in routine use today on the International Space Station (ISS). AirInSpace owns exclusive rights to this one-of-a-kind technology, which shows up to 99.999% single-pass inactivation of airborne microorganisms.
Headquartered in Sterling, Va., AirInSpace offers an innovative range of products and services to address the need for microbial decontamination of air in hospitals and other environments. For more information, please visit www.airinspace.com, or contact the company at: [email protected]